Sharing the news in a recent podcast episode, Katie Price explained that a "lot's gonna change" for her son, Harvey, who is ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Gray market grows for cheap weight-loss drugs imported from China, while some users try small doses of substances not yet ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Joie Armstrong asked her doctor about taking a GLP-1 medication to help her lose weight six times before she got a prescription, and then was denied coverage by her insurance company. Adrian, a ...

Katie Price has shared that her son Harvey will undergo a new medical regimen that is set to transform his appearance.

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

The Health Secretary’s 10-year plan includes proposals to bring down the cost of weight-loss drugs so more patients can get ...

Two growth stocks in the healthcare industry stand out in particular. Here is what you need to know about each one and why ...

Proponents say direct-to-consumer sales by drugmakers cut out intermediaries that add needlessly to prices. Detractors see ethical issues and prices that are still too high for many patients.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.